A polymerase chain reaction-based method to detect cisplatin adducts in specific genes

Area of Science:

• Molecular Biology
• Genetics
• Biochemistry

Background:

• Bulky DNA lesions can inhibit Taq DNA polymerase, reducing polymerase chain reaction (PCR) amplification.
• Quantifying DNA damage is crucial for understanding drug effects and developing therapies.

Purpose of the Study:

• To investigate the feasibility of using PCR inhibition to quantify DNA lesions induced by the anticancer drug cisplatin.
• To develop a sensitive method for detecting gene-specific DNA damage.

Main Methods:

• In vitro platination of hamster genomic DNA with cisplatin.
• PCR amplification of different DNA fragment sizes (150, 750, 2,000 bp) using [32P]dCTP.
• Quantification of DNA lesions by measuring PCR product radioactivity and inhibition.
• Analysis of cisplatin-induced lesions in the adenine phosphoribosyltransferase gene of CHO cells.

Main Results:

• PCR amplification inhibition correlated with the level of DNA platination across different fragment sizes.
• A significant decrease in 2 kbp fragment amplification was observed in CHO cells treated with 75 microM cisplatin.
• The 150 bp fragment showed no change in amplification, serving as a normalization control.
• The assay demonstrated sensitivity comparable to existing methods for gene-specific DNA damage analysis.

Conclusions:

• PCR inhibition is a viable method for quantifying cisplatin-induced DNA lesions.
• This assay provides a sensitive and direct approach to DNA damage detection, eliminating the need for specific endonuclease complexes.